Children’s Hospital of Wisconsin opened its MACC Fund Center clinical and Northwestern Mutual Day Hospital

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CHILDREN’S HOSPITAL OF WISCONSIN opened its MACC Fund Center clinic and Northwestern Mutual Day Hospital.

“Children’s Hospital of Wisconsin is grateful for its long standing partnership with the MACC Fund, an organization exceptionally dedicated to children with cancer and blood disorders,” said Peggy Troy, CEO of the Children’s Hospital of Wisconsin. “Through the support of the MACC Fund and Northwestern Mutual, we are able to continue our mission to advance diagnosis and treatments, provide excellence in clinical care, expand training and research efforts, and improve access and outcomes.”

The new care areas on the fifth floor of Children’s Hospital are co-located with the MACC Fund Center inpatient unit and critical care unit. Designed with the help of 10 former MACC Fund Center patients and their families, the renovation features a 10,384-square-foot clinic with the latest technology for improved care delivery, 18 exam rooms and a neuropsychiatric testing suite.

The 10,329-square-foot day hospital includes an activities center, 14 private infusion suites, and a specialized chemotherapy pharmacy.

“We are proud to introduce the Northwestern Mutual Day Hospital, which will enable the doctors, nurses and staff to provide a best-in-class experience to the patients and their families, integrating technology and support services,” said John Kordsmeier, president of the Northwestern Mutual Foundation. “When a child receives a cancer diagnosis, the family does as well. We want to help ensure that when a family is undergoing treatment, they have a family-friendly environment that allows kids to be kids.”

Since the MACC Fund Center program began in 1980: more than 5,000 children have received care through the Oncology Program; more than 1,000 children have received blood and marrow transplants; and 300 children are actively managed for sickle cell disease annually, and 250 new patients are treated for other blood disorders.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login